» Articles » PMID: 36451445

Network Pharmacology-based Strategy to Investigate Pharmacological Mechanism of Liuwei Dihuang Pill Against Postmenopausal Osteoporosis

Overview
Specialty General Medicine
Date 2022 Dec 1
PMID 36451445
Authors
Affiliations
Soon will be listed here.
Abstract

Postmenopausal osteoporosis (PMOP) has became 1 of most prevalent bone disorders with aging population. Liuwei Dihuang (LWDH) Pill, a classical kidney-tonifying prescription, is extensively used to treat PMOP in China. The aim of this study is to explore the pharmacological mechanisms of LWDH Pill against PMOP via network pharmacological strategy. The active ingredients of LWDH Pill were screened out from the Traditional Chinese Medicine System Pharmacology, Encyclopedia of Traditional Chinese Medicine and Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine Databases, and their related target genes were fished in the UniProt database. Simultaneously, the GeneCards and DisGeNET databases were used to identify the target genes of PMOP. Through establishing a protein-protein interaction network, the overlapping genes between LWDH Pill and PMOP were identified to analyze their interactions and the hub target genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed to predict the underlying biological processes (BP) and signaling pathways, respectively. A total of 64 active ingredients and 653 related target genes were identified in LWDH Pill, and 292 target genes were closely associated with PMOP. After matching the target genes between LWDH Pill and PMOP, 84 overlapping targets were obtained and considered as therapeutically relevant. Through construction of a protein-protein interaction network, we identified 20 hub target genes including IL6, INS, tumor necrosis factor, AKT1, vascular endothelial growth factor A, IGF1, TP53, IL1B, MMP9, JUN, LEP, CTNNB1, EGF, PTGS2, PPARG, CXCL8, IL10, CCL2, FOS and ESR1. Gene Ontology enrichment analysis suggested that LWDH Pill exerted anti-PMOP effects via regulating multiple BP including cell proliferation and apoptosis, oxidative stress, inflammation and angiogenesis. Kyoto Encyclopedia of Genes and Genomes enrichment analysis revealed several pathways, such as PI3K-AKT pathway, mitogen-activated protein kinase pathway, hypoxia-inducible factors-1 pathway, tumor necrosis factor pathway, interleukin-17 (IL-17) pathway and FoxO pathway that might be involved in modulating the above BP. Through network pharmacological approach, we investigated the potential therapeutic mechanism of LWDH Pill against postmenopausal osteoporosis in a systemic perspective. These identified multi-targets and multi-pathways provide promising directions for further revealing more exact mechanisms.

Citing Articles

Bioinformatics and network pharmacology discover the molecular mechanism of Liuwei Dihuang pills in treating cerebral palsy.

Wang L, Chen B, Xie D, Wang Y Medicine (Baltimore). 2024; 103(43):e40166.

PMID: 39470545 PMC: 11521014. DOI: 10.1097/MD.0000000000040166.


Targeting cellular senescence in senile osteoporosis: therapeutic potential of traditional Chinese medicine.

Zhang Y, Yu X, Zhou C, Fu K, Luo H, Wu C Front Med (Lausanne). 2023; 10:1288993.

PMID: 38076228 PMC: 10704475. DOI: 10.3389/fmed.2023.1288993.


Consequences of Aging on Bone.

Zhang L, Guan Q, Wang Z, Feng J, Zou J, Gao B Aging Dis. 2023; 15(6):2417-2452.

PMID: 38029404 PMC: 11567267. DOI: 10.14336/AD.2023.1115.


Mechanisms of action and synergetic formulas of plant-based natural compounds from traditional Chinese medicine for managing osteoporosis: a literature review.

Zhou C, Shen S, Zhang M, Luo H, Zhang Y, Wu C Front Med (Lausanne). 2023; 10:1235081.

PMID: 37700771 PMC: 10493415. DOI: 10.3389/fmed.2023.1235081.


Anti-inflammatory and antioxidant traditional Chinese Medicine in treatment and prevention of osteoporosis.

Li Q, Tian C, Liu X, Li D, Liu H Front Pharmacol. 2023; 14:1203767.

PMID: 37441527 PMC: 10335577. DOI: 10.3389/fphar.2023.1203767.

References
1.
Tang Y, Li M, Wang J, Pan Y, Wu F . CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems. 2014; 127:67-72. DOI: 10.1016/j.biosystems.2014.11.005. View

2.
Kim E, Jo C, Ryu S, Kim S, Lee J . Anti-osteoclastogenic diacetylenic components of Dendropanax morbifera. Arch Pharm Res. 2018; 41(5):506-512. DOI: 10.1007/s12272-018-1033-3. View

3.
Liu Y, Liu J, Xia Y . Chinese herbal medicines for treating osteoporosis. Cochrane Database Syst Rev. 2014; (3):CD005467. PMC: 10638660. DOI: 10.1002/14651858.CD005467.pub2. View

4.
Wang Z, Yang Y, He M, Wang R, Ma J, Zhang Y . Association between interleukin-6 gene polymorphisms and bone mineral density: a meta-analysis. Genet Test Mol Biomarkers. 2013; 17(12):898-909. PMC: 3865625. DOI: 10.1089/gtmb.2013.0223. View

5.
Herbert S, Stainier D . Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011; 12(9):551-64. PMC: 3319719. DOI: 10.1038/nrm3176. View